Sierra Oncology

Sierra Oncology is a clinical-stage pharmaceutical company with the mission of delivering targeted therapies for the treatment of rare cancers. Leveraging deep scientific expertise to identify compounds that address the root causes of diseases, our team employs an evidence-based approach to understand the limitations of current treatments and explore new ways to transform cancer treatment paradigms. The company is focused on the Phase 3 execution, registration, and commercialization of momelotinib, a novel drug candidate potentially addressing significant unmet needs in myelofibrosis. Momelotinib is a selective and orally bioavailable JAK1, JAK2, and ACVR1 inhibitor with a novel mechanism of action that enables it to potentially target all three hallmarks of myelofibrosis: anemia, constitutional symptoms, and splenomegaly.